国内散发本土疫情，海外疫情出现反扑。10 月17 日以来，国内出现 多点散发本土疫情，呈快速发展态势，一周之内已波及内蒙古、甘肃、 宁夏、北京、河北等11 个省份。截至10 月23 日，累计报告133 例感 染者。海外疫情亦出现反扑。俄罗斯单日新增病例和死亡病例均连创 新高，10 月23 日新增超3.5 万例确诊病例，新增1072 例死亡病例。 英国近7 天新增新冠确诊病例数创7 月下旬以来单周新增确诊病例最 高纪录。截至23 日，已连续11 天新增确诊超4 万例。

本周新药行情回顾：2021 年10 月18 日—2021 年10 月22 日，新药 板块，涨幅前5 企业：迈博药业（+6.5%）、药明巨诺（+6.0%）、百济 神州（+5.7%）、先声药业（+5.7%）、康宁杰瑞（+5.1%）； 跌幅前5 企业：亘喜生物（-21.3%）、前沿生物（-13.6%）、康诺亚（- 7.5%）、贝达药业（-7.5%）、德琪医药（-5.2%）。

The concept of aesthetic treatments using radiofrequency is not new and has been in the industry for well over a decade. However, the level of innovation has significantly increased during recent years. Prominently, the number of regulatory approvals and new offerings has increased during the pandemic. The global radiofrequency-based aesthetic devices market features a highly complex and competitive technological landscape. Technology is one of the primary differentiators in this field. Consequently, companies put a strong emphasis on the development of intellectual property (IP). Companies operating in the market have a vast array of products lined up, each of them compatible with their proprietary technology.

Currently, the field of radiation therapy is changing in terms of radiation type, and there are several changes in adoption patterns among its end-user segments. The end users are shifting from conventional radiation (Xray, or Cobalt-60, among others) to modern radiation such as a proton or heavy ion radiation. The increasing demand for modern radiation therapy systems has led to the increasing awareness of cancer/tumor treatments. The primary role of these systems is to shrink or destroy cancer/tumor depending on cancer/tumor type, stage, patient age, number of radiation sessions required, and many other factors. Radiation therapy can be divided primarily into external beam radiation therapy, also known as teletherapy, and internal beam radiation therapy, also known as brachytherapy. In the past decade, the definition of these technologies has expanded. Earlier the radiation therapy was only referred to as a simple therapy only done by the radiation beam. Now, radiation therapy includes internal radiation or external radiation combined with chemotherapy or open body surgery or combining various radiation therapy techniques such as IGRT, VMAT, and SRS to destroy or shrink cancer/ tumor. The ongoing trend of offering new radiation therapy systems which have proton or heavy ion beam, integration of two different radiation therapies, and integration of imaging technology with radiation therapy systems showcase the growing future of technological innovations and advancements in radiation therapy in the oncology field.

Practically overnight, clinicians, healthcare providers, pharmaceutical companies and payers shifted much of their work onto virtual platforms and other digital technologies. As consumers grappled with a deadly new virus, providers embraced virtual technology in unprecedented numbers so they could continue to serve patients despite restrictions on in-person interactions. In doing so, they packed a decade’s worth of reforms into a few short months. Players across the industry boosted data analytics capabilities to respond to ongoing shifts in healthcare needs, consumer behaviour and the economy. The deployment of digital tools in clinical trials helped companies quickly test whether existing medicines worked against the new virus and enabled the rapid development of COVID-19 vaccines. And work began to shore up the weaknesses evident in the healthcare supply chain. All this took place amid the broader backdrop of changes coursing through the industry and a set of long-standing common issues affecting the health ecosystem. In the years before the pandemic, and in the months since COVID-19 altered the course of history, a series of transformations has been altering traditional paradigms. And they will continue to do so in coming years. These include a heightened focus on well-being and prevention, the push to develop cures in addition to treatments, paying based on outcomes rather than fee-for-service, new developments in gene therapy and precision medicine, cross-industry convergence, and an end-to-end focus on patient and clinician experience. These themes intersect and interact with significant issues, including excessive cost; health inequities; inadequate transparency, interoperability and collaboration; and a general lack of trust.

The global surgical instrument tracking devices market is expected to grow at a CAGR of 9.16% for the forecast period 2021-2031. Leading market players strive to retain a competitive edge by having a good presence in key markets and offering a diverse product range. The market has witnessed a total of 32 key developments over the five years (January 2016-March 2021), with a majority of them being product offerings and upgradation accompanied by partnerships, alliances, and business expansions. Efforts are being made to bring more technologically innovative goods to market, each aimed at a particular unmet need. With the launch of new and updated devices with improved features, surgical instrument tracking devices technology has become increasingly possible to unlock new use cases.

Direct-to-consumer genetic tests (DTC-GT) offers its consumers the ability to solve their individual genetic puzzle. The confluence of breakthroughs in genetic testing has not only decreased the time required to perform a genetic test but also has reduced the cost of conducting these tests. All these factors combined have given DTC-GT a lot of acceptance among the consumers. The major proponent of the DTC-GT market is the distribution channels opted by the companies. The companies are marketing these tests via online or retail channels. With the piqued advertisements of these tests through print, media, and the internet, the industry is gaining familiarity among consumers. Companies such as 23andme, Mapmygenome, Ancestry.com, EasyDNA, and 24Genetic are offering a large number of diversified services related to genealogy testing, health conditions, and traits. The journey of the DTC-GT initiates by a consumer ordering the test through an online channel. The sample collection kit is provided to the consumers. DNA sample such as saliva or oral swab is collected by the consumer and sent back to the organization for the analysis. Consumers get their test results on their online account within 3-5 weeks.

The Food and Drug Administration (FDA) regulates medical devices in the U.S. to ensure their effectiveness and safety for patients and users. The FDA's Center for Devices and Radiological Health (CDRH) oversees regulating these firms. The FDA must approve every company involved in the manufacturing, packaging, labeling, and/or sale of medical devices sold in the U.S. Electrocardiographs are classified into Class II categories of medical devices in the U.S. These systems are considered as medical devices through the Federal Food, Drug and Cosmetic (FD&C) Act. Diagnostic imaging systems are classified under the category of non-501(k)-exempt Class I and Class II medical devices and do not follow the Pre-Marketing Approval (PMA) pathway by U.S. Food and Drug Administration (FDA). In 501(k) pathways, any new diagnostic imaging devices under Class I and Class II should be legally marketed and should have a clear definition of technological characteristics, applications, and indications.